SKP2 overexpression has been associated with poor patient survival and drug resistance in a variety of human cancers and its reported oncogenic properties appear to be linked mainly to reduced p27 levels allowing increased tumor cell proliferation [46, 47]. The gene discussed is CDKN1B; the disease is cancer.